The Emirates Drug Corporation announced the registration of the drug “Pylentamab Mavodotin) as an innovative treatment for multi -tumor patients who suffer from a setback or resistance to previous treatments, thus becoming the third country in the world that adopts this property after the United Kingdom and Japan, in a strategic achievement that embodies the state’s pre -emptive approach to accelerating access to advanced treatments, and reflects the commitment of the institution to build a pharmaceutical system Flexible contributes to enabling patients to obtain effective treatment solutions in time. Therapeutic options and the drug forms a qualitative addition to the multi -tumor treatment protocols, which is one of the most complex and spreading types of blood cancers,
source
